Second-generation basal insulins improve glycaemic control

Second generation basal insulin revolution - Home page 2nd line

Second-generation basal insulins are particularly beneficial to diabetes patients with marked variability in glucose levels, frequent all-day and/or nocturnal hypoglycaemia despite optimisation of current insulin analogue regimen

You will gain an understanding and awareness of:

  • The fundamental principles of an integrated approach to diabetes treatment with the goal of avoiding glycaemic variability and hypoglycaemia
  • The use of continuous glucose monitoring (CGM) and interpretation of time-in-range (TIR) data to improve diabetes care
  • The clinical evidence supporting second-generation basal insulin analogues for improving glucose variability control/TIR in patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM)
  • Practical, actionable clinical practice pointers for identifying those patients who will benefit most from second-generation basal analogue insulin therapy and the manner in which those patients who are currently using other insulin treatments can safely switch therapies.

To access this module, please register or login: